116 results about "CD36" patented technology

The invention provides a depression diagnosis marker which is selected from one or more of immune cell Trem1 classical mononuclear cells, B cells, CD36 mononuclear cells, HLADR mononuclear cells, Th17, Treg, cell factors CXCL14, VEGFR1IL-1, RII, RANK, XEDAR, GITR, CRTAM, IL-11, IGFBP-2 and Fetuin A. The depression diagnosis marker has high MDD curative effect prediction efficiency. The invention further discloses application of the depression diagnosis marker in preparation of products for diagnosing depression, and the depression diagnosis marker has high MDD diagnosis value.

The present invention relates to the technical field of genetic engineering. Particularly provided are an identification marker for early chronic obstructive pulmonary disease and the use thereof in a diagnostic kit. The identification marker for the early chronic obstructive pulmonary disease is screened, which is miRNA1255a in serum-derived exosomes; in addition, biological function analysis after sequencing proves that among a plurality of target genes of miRNA1255a, the tissue inhibitor of metalloprotease (TIMP-2) and CD36, which are genes related to the protease / antiprotease balance, are involved in the Ca ion signaling pathway, and moreover, the expression of CD36 and TIMP-2 proteins proves that said two proteins are negatively correlated with miRNA1255a. Moreover, it is found in detection results that the expression of TIMP-2 and the expression of CD36 are all downregulated when the expression of miRNA1255a is upregulated. The biomarker for the early chronic obstructive pulmonary disease is provided, which can easily screen potential patients with early onset of chronic obstructive pulmonary disease.

The invention belongs to the technical field of biomedical materials, and discloses light-controlled liquefied hydrogel for inhibiting wound scar formation and a preparation method and application thereof.The light-controlled liquefied hydrogel is prepared from 6-18 parts of PVA hydrogel, 3-9 parts of borax boric acid buffer solution and 1-3 parts of PDA (at) CeO2-SAB nano-particle suspension.The hydrogel has the advantages that light-controlled liquefaction can be achieved, and the hydrogel can be applied to wound scar formation. The material has the characteristics of uniform particle size, accurate drug release, inhibition of CD36 expression, good biocompatibility, biodegradability and the like, can be used for infected wounds, and provides a novel, simple and effective material for wound inflammation inhibition and scar repair resistance treatment.

The invention discloses a biomarker for predicting recurrence and metastasis risks of breast cancer and application of the biomarker. The invention discloses application of a substance for detecting a biomarker in preparation of a product for predicting the recurrence or metastasis risk of breast cancer. The biomarker comprises one or more of FBLN5, MUC16, ORM1, ADH1B, CD36, KRT19, DCD, DEFA3, RNASE1 and KLHL22. The invention further constructs a breast cancer recurrence or metastasis risk prediction model. According to the biomarker and the breast cancer recurrence or metastasis risk prediction model, the breast cancer recurrence or metastasis risk can be accurately, noninvasively and efficiently predicted, and clinical requirements can be met.

Targeting metastasis stem cells through a fatty acid receptor. The disclosure provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

The present disclosure generally relates to binding agents capable of targeting tumor cells and / or immune cells and their use to treat cancer. The binding agents of the present disclosure comprise one or more antigen-binding domains of a single-domain antibody capable of binding to cluster of differentiation 36 (CD36), programmed cell death protein 1 (PD-1), and / or cluster of differentiation 47 (CD47). The binding agents of the present disclosure may be monospecific or multispecific and may be in monomeric or multimeric form.

The standard of care for cancer patients comprises administration of broadly cytotoxic agents with no direct anti-tumor activity. Such treatments present with debilitating side effects and are prone to the development of resistance. Accordingly, there is a need for improved cancer therapeutics that are directly anti-tumorigenic and antimetastatic. The present technology relates to methods and compositions for improved cancer therapy. In particular, the present technology relates to determining the levels of CD36 and CD47 in a cancer and administering agents that modulate their activities, wherein the cancer demonstrates elevated CD36 and CD47 levels or activity.

The present invention relates to the technical field of biology, and particularly relates to a method for inhibiting an inflammatory response by using a fibroblast. In the present invention, a fibroblast, which is obtained by digesting normal foreskin tissue by means of clostridiopeptidase A to isolate a cell as a seed cell and culturing the seed cell in vitro by using a serum-free medium, shows positive expression of CD105, CD90, CD73, COL1A1, and FAP, with expression rates all exceeding 80%, and negative expression of CD36, CD39, CD45, and HLA class II molecules, with expression rates below 5%. The fibroblast can regulate an immune response by secreting TGFβ, inhibiting proliferation of PBMCs, thereby inhibiting the inflammatory response, and has been verified in an animal experiment to have the ability to repair knee osteoarthritis caused by meniscus injury. Therefore, the fibroblast can be used for preventing and treating inflammatory lesions such as osteoarthritis.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The invention discloses application of a CD36 inhibitor in preparation of a medicine for treating psoriasis, and belongs to the technical field of biological medicine. Experiments prove that the ointment containing the CD36 inhibitor can significantly reduce the expression level of psoriasis related inflammatory factors CXCL5 / CXCL8 and CCL20, and reduce the local infiltration of CCR6 + T cells and neutrophils. The CD36 inhibitor ointment can inhibit secretion of inflammatory chemotactic factors related to keratinocyte psoriasis so as to effectively relieve psoriasis-like dermatitis induced by IMQ, and can be used for preparing local external medicines for treating psoriasis.

The invention provides application of HK2 in preparation of hematoma removing medicine for treating cerebral hemorrhage. Experiments prove that HK2 enhances the phagocytic function of microglial cells by regulating and controlling a PPARgamma / CD36 signal channel, so that hematoma removal is promoted, the neurological function is improved, and the HK2 has important significance.

Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

The present application provides siRNA and its application for specifically inhibiting CD36 gene expression. In particular, the present application provides siRNA, shRNA, recombinant vector, recombinant lentivirus, siRNA, host cell for specifically inhibiting CD36 gene expression, and its application in preparing a medicament for inhibiting CD36 gene expression / treating CD36 related diseases.

The invention discloses an antibody composition for solid tumor detection and application thereof. The antibody composition comprises a CD45 antibody, a CD56 antibody, a CD9 antibody, a CD81 antibody, a CD36 antibody, a GD2 antibody, an HLA-DR antibody, a CD326 antibody, a CD7 antibody, a CD138 antibody, a CD19 antibody and a CD4 antibody. The antibody composition disclosed by the invention can be used for detecting solid tumor cells by flow cytometry, and can effectively define CD56 + tumor cells and CD56-tumor cells, so that the CD56 + tumor cells and the CD56-tumor cells cover the most complete solid tumor cell groups originated from ganglions, neuroendothelium, mesenchymal origin and the like, and the missed diagnosis probability is reduced.

The invention discloses siRNA delivery lipid nanoparticles for targeted inhibition of GPNMB expression in macrophage-derived foam cells and application of the siRNA delivery lipid nanoparticles, and belongs to the technical field of biology. According to the siRNA delivery lipid nanoparticle, the lipid nanoparticle serves as a carrier, siGpnmb is loaded on the carrier, monoclonal antibodies of CD36 and TREM2 are coupled to the surface of the carrier, the CD36 monoclonal antibody and the TREM2 monoclonal antibody serve as target heads of an antibody-LNP-siRNA compound, and the lipid nanoparticle loaded with the siGpnmb can be delivered into foam cells in a targeted mode. The siGpnmb released in the foam cells can inhibit the expression of GPNMB, so that the autophagy level in the foam cells is improved, the lysosome degradation capability is enhanced, and the overall foaming level is obviously reduced, thereby reducing the lipid core burden in vascular plaques and realizing the treatment of atherosclerosis.

The invention discloses application of targeting CD36 in treatment of rheumatoid arthritis, and relates to the technical field of biological materials, and the technical key points are as follows: the CD36 is an effective target spot for treating the rheumatoid arthritis, the content of the CD36 in the body of an RA patient is reduced, and RA-FLS proliferation and release of inflammatory factors can be inhibited; a new molecular mechanism that CD36 participates in RA-FLS activation by regulating fatty acid metabolism is found, CD36 is a new target for relieving RA joint inflammation and injury, and a new treatment direction is provided for clinical treatment of RA.

The present invention discloses a preparation method and application of a self-assembling polypeptide targeting CD36 protein, belonging to the technical field of biomedicine. The self-assembling polypeptide is composed of an R3 specific targeting unit, an R2 self-assembling unit, and an R1 hydrophobic unit sequentially connected by amide bonds. The R1 hydrophobic unit is an alkyl carboxylic acid with C8-C20, the R2 self-assembling unit is a multiple hydrogen bond polypeptide sequence, and the R3 specific targeting unit is a polypeptide with specific targeting to CD36 protein screened from a polypeptide library. The self-assembling polypeptide of the present invention can bind to CD36. The self-assembling polypeptide of the present invention is obtained by solid-phase synthesis method, and has many advantages such as small relative molecular weight, high specificity, and low cost. It shows unique advantages in the targeted diagnosis and treatment of tumors, and has extremely important and extensive application prospects and good economic and social effects.

The application discloses a kind of magnetic nanoparticles for atherosclerosis diagnosis and treatment.It is core-shell structure, the inner core is Fe₃O₄ magnetic nano material, shell is the drug-loading layer of biodegradable polymer material, the drug-loading layer is encapsulated with analog movement polypeptide K271la, and the surface of nano particle is covalently coupled with CD36 targeting antibody.Its preparation method mainly includes: by complex emulsification-solvent volatilization method, Fe₃O₄ nanoparticle and K271la polypeptide are co-encapsulated in one step, form nanoparticle, and then CD36 antibody is modified on the surface of particle by chemical coupling.The nanoparticle of the application has the ability of active targeting (CD36 antibody) and passive targeting (magnetic response), can be efficiently enriched in plaque, and deliver therapeutic polypeptide to macrophages, activate lipophagy to remove lipid;It can be used as magnetic resonance imaging contrast agent, realizes diagnosis and treatment integration, and provides a new strategy for solving the problem of low efficiency of atherosclerosis targeted therapy and lack of effective monitoring means.

The invention relates to the technical field of biomedicine, in particular to cyclic polypeptide targeting CD36 protein and a radioactive tracer derived from the cyclic polypeptide. The preparation method comprises the following steps: condensing cyclic polypeptide targeting CD36 protein and dipolyethylene glycol serving as a connexon, coupling a chelating agent NOTA to form a labeled precursor NOTA-ZL01 targeting the CD36 protein, labeling radionuclide with the labeled precursor NOTA-ZL01 targeting the CD36 protein to form a radioactive tracer [68Ga] Ga-ZL01, and carrying out a reaction on the radioactive tracer [68Ga] Ga-ZL01 and the labeled precursor NOTA-ZL01 and the labeled precursor NOTA-ZL01 targeting the CD36 protein. Through in-vitro radiochemical property research and in-vivo stability research, the radioactive tracer [68Ga] Ga-ZL01 is found to be high in stability and hydrophilic; through cell uptake research and receptor binding force research, it is found that the radioactive tracer [68Ga] Ga-ZL01 has high affinity to CD36 protein expressed by U87 cells; the tumor imaging effect of the radioactive tracer [68Ga] Ga-ZL01 is investigated through small animal PET / CT, and it is found that the radioactive tracer [68Ga] Ga-ZL01 can be used for in-vivo imaging of CD36 positive glioblastoma.

The invention provides a biomarker combination for evaluating the progress of abdominal aortic aneurysm based on an adventitia and application of the biomarker combination, and the biomarker combination comprises at least two biomarkers selected from the following three independent groups, the at least two markers are from the same group or different groups: a myofibroblast transformation marker group: alpha-smooth muscle actin, monocyte chemotactic protein 1 and a tissue metalloproteinase inhibitor 1; the lipid metabolism related biomarker group comprises a lipid metabolism related protein CD36, carnitine palmitoyl transferase 1 and a fatty acid binding protein 4; and an inflammatory factor related biomarker group: IL-6, MCP-1 and TIMP1. According to the biological marker combination for evaluating the progress of the abdominal aortic aneurysm based on the adventitia, multi-channel biological markers are systematically integrated, an innovative tool is provided for accurate diagnosis, drug screening and curative effect monitoring of AAA, and meanwhile, an important foundation is laid for developing a collaborative treatment strategy based on adventitia fibroblast regulation.

The present invention discloses a diagnostic kit for autism spectrum disorder based on pan-apoptosis-related genes, which belongs to the field of biomedicine. The diagnostic kit for autism spectrum disorder based on the pan-apoptosis-related genes of the present invention includes a detection kit. <h2 style=";text-align:left;direction:ltr">CD36 <h2 style=";text-align:left;direction:ltr"> LMNB1, DNAJA1, MSH2, JAK2, PDCD4, DEK This study identified and screened key pan-apoptosis genes that were differentially expressed between children with autism spectrum disorder and healthy children. Using primer sequences for these key pan-apoptosis genes and internal reference genes, a diagnostic kit was constructed to calculate autism risk based on the expression levels of these key genes. External sample validation of the kit and its diagnostic efficacy was conducted, demonstrating positive results.

The present invention addresses the problem of providing: a genetically modified cultured cell or a genetically modified animal each allowing a human sapovirus to proliferate regardless of host characteristics as barriers to proliferation in mammalian cells; and an application of the cell or animal to a screening method. The present inventors have solved the problem by finding that a genetically modified cultured mammalian cell having a human CD36-encoding gene incorporated therein and a mammal having such a cell as a self-cell show acquired susceptibility to human sapovirus infection, and providing, for example, a screening method for a drug relevant to a human sapovirus on the basis of the finding.

The present invention discloses a pharmaceutical application of a CD36 inhibitor. Based on the CD36 protein structure, through the Virtual Flow virtual drug screening platform, the top 100 small molecules are screened from the drug target library for actual screening to screen for active small molecules that inhibit the function of the CD36 protein, and the effectiveness of the active small molecules of CD36 is characterized by inhibiting the oxLDL uptake level. Six potential active compounds including F449-4678 are screened out from the active small molecules. Through MST small molecule and protein binding affinity test, Dil-oxLDL flow cytometry is used to detect the IC50 of the small molecule inhibitor, and CCK-8 is used to detect cell proliferation; in addition, it is verified on LLC-LUC xenograft tumor mice that when the active small molecule is administered to the mice, it can effectively inhibit the growth of tumors, thereby achieving an anti-tumor effect.

The invention provides a novel cholestatic liver disease treatment method based on circadian rhythm. Researches find that in a biliary duct ligation (BDL)-induced liver injury model, the rhythmic expression of CD36 is enhanced and reaches a peak value at ZT16. SiCD36 is delivered by using lipid nanoparticles (LNP) at a ZT10 time point, and expression increase of CD36 can be effectively inhibited at ZT16, so that liver injury and inflammatory response caused by cholestasis are remarkably relieved. Serum and liver biochemical analysis shows that the strategy reduces the levels of alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), cholesterol and total bile acid, and improves liver lipid metabolism. The invention provides a new treatment thought and target for chronic cholestatic liver diseases such as PBC and PSC, and shows the potential application value of circadian rhythm in precision medicine.

The invention belongs to the technical field of stem cell biological medicine, and particularly relates to application of uterine blood mesenchymal stem cell outer vesicles. According to the application, external vesicles (MenSC-EVs) derived from MenSC are used as active ingredients, the MenSC-EVs effectively relieve the hepatic fibrosis condition of a mouse, the key effect of a Thbs1 / Cd36 signal on mediating intercellular communication in a fibrosis hepatic microenvironment is disclosed, and the therapeutic effect of the MenSC-EV on hepatic fibrosis and a potential molecular mechanism of the MenSC-EV are explored and confirmed.

The invention provides a polypeptide for inhibiting fat accumulation and application of the polypeptide. The amino acid sequence of the polypeptide is MNGLTLGSIPKEEAEKERQGWLEAAK. The polypeptide can inhibit transport of extracellular fatty acids by CD36, reduce lipid uptake and accumulation of cells, and effectively inhibit accumulation of intracellular triglyceride and other fats caused by free fatty acids.